CSF DRUG LEVELS FOR CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA TREATED BY 5 G/M2 METHOTREXATE - A STUDY FROM THE EORTC CHILDRENS LEUKEMIA COOPERATIVE GROUP

被引:26
作者
MILANO, G
THYSS, A
DEBEAUVAIS, FS
LAUREYS, G
BENOIT, Y
DEVILLE, A
DUTOUR, C
ROBERT, A
OTTEN, J
BEHAR, C
FRAPPAZ, D
机构
[1] CHU GRENOBLE, F-38043 GRENOBLE, FRANCE
[2] KLIN KINDERZIEKTEN, GHENT, BELGIUM
[3] HOP PURPAN, TOULOUSE, FRANCE
[4] VRIJE UNIV BRUSSELS, ACAD ZIEKENHUIS, B-1050 BRUSSELS, BELGIUM
[5] HOP AMER, REIMS, FRANCE
[6] HOP A MICHALON, GRENOBLE, FRANCE
关键词
D O I
10.1016/0277-5379(90)90023-M
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A multicenter EORTC study was conducted in children with acute lymphocytic leukemia to determine whether 5 g/m2 of methotrexate (MTX) (24 h i.v. infusion, four cycles) is an appropriate dosage for obtaining CSF drug concentrations approaching the critical cytotoxic level of 10-6 M. A total of 193 cycles were analyzed for 58 patients. At the end of the 24 h infusion, the mean MTX serum level was 65.27 ± 33.11 μM; the mean CSF MTX level was 1.47 ± 1.1 μM; no significant difference in CSF MTX levels was observed between patients with (n = 20) and those without i.v. Ara-C (n = 38). The mean CSF MTX/serum MTX ratio was 0.029 ± 0.027. CSF drug concentrations greater than or equal to 10-6 M were achieved in 81% of the courses. The highest level was 8.4 × 10-6 M. Only 5% of patients failed to achieve this drug concentration in at least one cycle. No significant correlation was observed between blood and CSF MTX levels. Mean CSF MTX levels were comparable from one cycle to another. © 1990.
引用
收藏
页码:492 / 495
页数:4
相关论文
共 25 条
[1]   HIGH-DOSE METHOTREXATE - A CRITICAL REAPPRAISAL [J].
ACKLAND, SP ;
SCHILSKY, RL .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (12) :2017-2031
[2]  
ALLEN JC, 1980, CANCER TREAT REP, V64, P1261
[3]   REMISSION INDUCTION OF MENINGEAL LEUKEMIA WITH HIGH-DOSE INTRAVENOUS METHOTREXATE [J].
BALIS, FM ;
SAVITCH, JL ;
BLEYER, WA ;
REAMAN, GH ;
POPLACK, DG .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (04) :485-489
[4]  
BODE U, 1980, CANCER RES, V40, P2184
[5]  
BORSI JD, 1987, CANCER, V60, P5, DOI 10.1002/1097-0142(19870701)60:1<5::AID-CNCR2820600103>3.0.CO
[6]  
2-D
[7]  
ETTINGER LJ, 1982, CANCER, V50, P444, DOI 10.1002/1097-0142(19820801)50:3<444::AID-CNCR2820500311>3.0.CO
[8]  
2-#
[9]   METHOTREXATE CEREBROSPINAL-FLUID AND SERUM CONCENTRATIONS AFTER INTERMEDIATE-DOSE METHOTREXATE INFUSION [J].
EVANS, WE ;
HUTSON, PR ;
STEWART, CF ;
CAIRNES, DA ;
BOWMAN, WP ;
RIVERA, G ;
CROM, WR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (03) :301-307
[10]  
EVANS WE, 1986, APPLIED PHARMACOKINE, P1009